Edwards Lifesciences Corp Stock Performance
| EW Stock | USD 69.29 1.34 1.97% |
The firm shows a Beta (market volatility) of 0.42, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edwards Lifesciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Edwards Lifesciences is expected to be smaller as well. At this point, Edwards Lifesciences Corp has a negative expected return of -0.0992%. Please make sure to confirm Edwards Lifesciences' maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Edwards Lifesciences Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Edwards Lifesciences Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Edwards Lifesciences is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 1.97 | Five Day Return (0.27) | Year To Date Return (4.55) | Ten Year Return 179.7 | All Time Return 4.9 K |
Last Split Factor 3:1 | Last Split Date 2020-06-01 |
1 | Disposition of 4559 shares by Andrew Dahl of Edwards Lifesciences at 87.62 subject to Rule 16b-3 | 12/20/2024 |
2 | Q4 2024 Integra Lifesciences Holdings Corp Earnings Call Transcript | 02/26/2025 |
3 | Disposition of 21910 shares by Bruls Annette of Edwards Lifesciences at 92.85 subject to Rule 16b-3 | 03/04/2025 |
4 | Edwards Lifesciences Corp Shares Gap Down to 69.395 on Mar 7 | 03/07/2025 |
5 | Edwards Lifesciences Corporation Among the Top Stocks to Buy According to Citadel Investment Group | 03/10/2025 |
6 | Former Masimo CEO Kiani wants court to toss empty voting lawsuit | 03/11/2025 |
7 | Signum Surgical Appoints Carol Burns as CEO | 03/12/2025 |
8 | Insider Selling Edwards Lifesciences Co. CEO Sells 428,459.64 in Stock | 03/13/2025 |
9 | More Unpleasant Surprises Could Be In Store For Nectar Lifesciences Limiteds Shares After Tumbling 27 | 03/14/2025 |
| Begin Period Cash Flow | 1.1 B |
Edwards |
Edwards Lifesciences Relative Risk vs. Return Landscape
If you would invest 7,412 in Edwards Lifesciences Corp on December 17, 2024 and sell it today you would lose (483.00) from holding Edwards Lifesciences Corp or give up 6.52% of portfolio value over 90 days. Edwards Lifesciences Corp is generating negative expected returns and assumes 1.6418% volatility on return distribution over the 90 days horizon. Put differently, 14% of stocks are less risky than Edwards on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Edwards Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edwards Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edwards Lifesciences Corp, and traders can use it to determine the average amount a Edwards Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0604
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EW |
Estimated Market Risk
| 1.64 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Edwards Lifesciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edwards Lifesciences by adding Edwards Lifesciences to a well-diversified portfolio.
Edwards Lifesciences Fundamentals Growth
Edwards Stock prices reflect investors' perceptions of the future prospects and financial health of Edwards Lifesciences, and Edwards Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edwards Stock performance.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0826 | ||||
| Profit Margin | 0.77 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 37.46 B | ||||
| Shares Outstanding | 587.9 M | ||||
| Price To Earning | 32.77 X | ||||
| Price To Book | 4.07 X | ||||
| Price To Sales | 7.49 X | ||||
| Revenue | 5.44 B | ||||
| Gross Profit | 4.32 B | ||||
| EBITDA | 1.72 B | ||||
| Net Income | 4.17 B | ||||
| Cash And Equivalents | 769 M | ||||
| Cash Per Share | 2.81 X | ||||
| Total Debt | 700 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.83 X | ||||
| Book Value Per Share | 16.99 X | ||||
| Cash Flow From Operations | 542.3 M | ||||
| Earnings Per Share | 2.34 X | ||||
| Market Capitalization | 40.74 B | ||||
| Total Asset | 13.06 B | ||||
| Retained Earnings | 13.17 B | ||||
| Working Capital | 4.78 B | ||||
| Current Asset | 2.05 B | ||||
| Current Liabilities | 476.2 M | ||||
About Edwards Lifesciences Performance
Evaluating Edwards Lifesciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Edwards Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edwards Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 354.94 | 372.69 | |
| Return On Tangible Assets | 0.41 | 0.43 | |
| Return On Capital Employed | 0.12 | 0.14 | |
| Return On Assets | 0.32 | 0.34 | |
| Return On Equity | 0.42 | 0.44 |
Things to note about Edwards Lifesciences Corp performance evaluation
Checking the ongoing alerts about Edwards Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edwards Lifesciences Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edwards Lifesciences generated a negative expected return over the last 90 days | |
| Edwards Lifesciences is unlikely to experience financial distress in the next 2 years | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: More Unpleasant Surprises Could Be In Store For Nectar Lifesciences Limiteds Shares After Tumbling 27 |
- Analyzing Edwards Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edwards Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Edwards Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edwards Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edwards Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edwards Lifesciences' stock. These opinions can provide insight into Edwards Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.